← Eichor
Study identifier: NCT06517875 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis

Condition: Primary Myelofibrosis · Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis  ·  Sponsor: GlaxoSmithKline

PhasePhase 2
Planned participants68
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this Phase 2 study is to evaluate the efficacy and safety of momelotinib (MMB) in combination with luspatercept (LUSPA) in participants with transfusion dependence (TD) primary myelofibrosis (PMF) or Post-polycythemia vera (PV)/ essential thrombocythemia (ET) myelofibrosis (MF) who are either janus kinase (JAK) inhibitor (JAKi) naïve or experienced.

This description comes directly from the study's public registry record.

Talk to the study team

US GSK Clinical Trials Call Center  ·  877-379-3718  ·  GSKClinicalSupportHD@gsk.com

EU GSK Clinical Trials Call Center  ·  +44 (0) 20 89904466  ·  GSKClinicalSupportHD@gsk.com

Always discuss trial participation with your own doctor first.

Locations (33)

GSK Investigational SiteAnn Arbor, Michigan, United StatesRecruiting
GSK Investigational SiteNew York, New York, United StatesRecruiting
GSK Investigational SiteNashville, Tennessee, United StatesRecruiting
GSK Investigational SiteHouston, Texas, United StatesRecruiting
GSK Investigational SiteSeattle, Washington, United StatesRecruiting
GSK Investigational SiteVancouver, British Columbia, CanadaRecruiting
GSK Investigational SiteToronto, Ontario, CanadaRecruiting
GSK Investigational SiteMontreal, Quebec, CanadaRecruiting
GSK Investigational SiteMontreal, Quebec, CanadaRecruiting
GSK Investigational SiteAngers, FranceRecruiting
GSK Investigational SiteBrest, FranceRecruiting
GSK Investigational SiteLyon, FranceRecruiting

+ 21 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06517875